|Awarded On||August 19, 2020|
|Title||Small RNA Nanovector based Targeted Immunotherapy for Glioblastoma|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas Health Science Center at Houston|
|Principal Investigator/Program Director||Tae Jin Lee|
|Cancer Sites||Brain and Other Nervous System|
*Pending contract negotiation
Glioblastoma (GBM) patients, one of the most deadly forms of human cancer, have not been benefited from the recent progress in immune checkpoint inhibitor-based immunotherapy mainly due to immune edition from aberrant dysregulation of gene expressions in tumor cells and poor innate immune response from tumor-supportive tumor microenvironment (TME) that is educated by tumor cell-secreting immunosuppressive cytokines. In order to prime the "cold" tumor cells and the immunosuppressive TME including tumor-associated macrophages (TAMs) to become sensitive to such attractive immunotherapy, their aberrantly deregulated gene expressions across various signaling pathways need to be reprogrammed by gl...